Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.6 AUD | +1.12% | -1.10% | +1.12% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
- The company presents an interesting fundamental situation from a short-term investment perspective.
- According to Refinitiv, the company's ESG score for its industry is good.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- The company has attractive valuation levels with a low EV/sales ratio compared with its peers.
- The company is one of the best yield companies with high dividend expectations.
- For the last few months, EPS revisions have remained quite promising. Analysts now anticipate higher profitability levels than before.
- Consensus analysts have strongly revised their opinion of the company over the past 12 months.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- The potential for earnings per share (EPS) growth in the coming years appears limited according to current analyst estimates.
- The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
- The company appears highly valued given the size of its balance sheet.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+1.12% | 6.39B | C+ | ||
+12.56% | 9.58B | B- | ||
+11.67% | 5.82B | C | ||
+91.91% | 4.16B | - | ||
+1.49% | 2.31B | B+ | ||
-20.94% | 1.01B | C | ||
+3.85% | 862M | - | D+ | |
+78.12% | 718M | - | C | |
+3.36% | 155M | - | - | |
-8.15% | 68.79M | - | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- MPL Stock
- Ratings Medibank Private Limited